Significantly Improved Results for Medtronic's Evolut TAVR seen in the Optimize PRO Study

At this year's EuroPCR meeting, the interim results of the Optimize PRO study of Medtronic's Evolut ™ PRO and PRO+ TAVR systems in 400 patients were presented as a Hotline Trial: permanent pacemaker rates dropped to single digits (9.2%) and the number of patients with moderate or severe paravalvular leak (PVL) was zero (78% of patients had no or only trace PVL). Moreover, the median length of ho spital stay was one day.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news